Weekly Cardiology Research Analysis
This week centers on randomized trials and high-impact imaging/anticoagulation advances that could change practice: a phase 2/3 randomized NEJM trial shows factor XI inhibition with monthly abelacimab markedly reduces bleeding versus rivaroxaban in atrial fibrillation; SCOT-HEART presents 10‑year randomized evidence that CCTA-guided management lowers coronary heart disease death or non-fatal MI via sustained preventive therapy optimization; and a prespecified ARTESiA subgroup gives randomized su
Summary
This week centers on randomized trials and high-impact imaging/anticoagulation advances that could change practice: a phase 2/3 randomized NEJM trial shows factor XI inhibition with monthly abelacimab markedly reduces bleeding versus rivaroxaban in atrial fibrillation; SCOT-HEART presents 10‑year randomized evidence that CCTA-guided management lowers coronary heart disease death or non-fatal MI via sustained preventive therapy optimization; and a prespecified ARTESiA subgroup gives randomized support for apixaban in device-detected subclinical AF with prior stroke/TIA. Mechanistic and translational studies (immunometabolism and ubiquitination pathways) and AI-enabled prognostic tools complement these clinical results, pointing to new therapeutic targets and implementation priorities.
Selected Articles
1. Abelacimab versus Rivaroxaban in Patients with Atrial Fibrillation.
In a randomized multicenter trial, monthly subcutaneous abelacimab (90 or 150 mg) profoundly suppressed free factor XI (~97–99%) and reduced major or clinically relevant nonmajor bleeding by roughly 62–69% versus rivaroxaban, prompting early trial termination for safety benefit; adverse events otherwise were similar across arms.
Impact: Provides randomized evidence that targeting factor XI can decouple anticoagulation from hemostasis, offering a bleeding-sparing strategy that could transform stroke-prevention paradigms in AF if efficacy for ischemic endpoints is confirmed.
Clinical Implications: If subsequent analyses confirm noninferior stroke/systemic embolism prevention, abelacimab (monthly subcutaneous) could be considered as a lower-bleeding alternative to DOACs for AF patients at high bleeding risk, changing anticoagulation counseling and logistics.
Key Findings
- Median free factor XI reduction at 3 months: ~99% (150 mg) and ~97% (90 mg).
- Major or clinically relevant nonmajor bleeding incidence: 3.2 and 2.6 vs 8.4 events/100 person‑years (150/90 mg vs rivaroxaban); HRs 0.38 and 0.31 (P<0.001).
- Trial stopped early for greater‑than‑anticipated bleeding reduction with abelacimab; overall adverse event rates similar.
2. Coronary CT angiography-guided management of patients with stable chest pain: 10-year outcomes from the SCOT-HEART randomised controlled trial in Scotland.
SCOT-HEART 10-year analysis (n=4146) found that adding CCTA to standard care reduced the composite of coronary heart disease death or non-fatal MI (6.6% vs 8.2%; HR 0.79, p=0.044), driven by fewer non-fatal MIs and MACE; preventive therapy prescribing remained higher in the CCTA arm over the decade.
Impact: Long-term randomized evidence that imaging-guided identification of coronary atherosclerosis leads to sustained risk-reducing preventive care; directly relevant to diagnostic algorithms for stable chest pain worldwide.
Clinical Implications: Consider routine use of CCTA for evaluation of stable chest pain to refine diagnosis and intensify preventive therapies (lipid-lowering, antiplatelet decisions), expecting sustained reductions in non-fatal MI and MACE over a decade.
Key Findings
- Primary outcome (CHD death or non-fatal MI) over median 10 years: 6.6% (CCTA) vs 8.2% (standard care); HR 0.79 (p=0.044).
- Non-fatal MI and MACE were significantly lower in CCTA group; revascularization rates were similar.
- Preventive therapy prescriptions remained more frequent in the CCTA arm across follow-up.
3. Apixaban versus aspirin for stroke prevention in people with subclinical atrial fibrillation and a history of stroke or transient ischaemic attack: subgroup analysis of the ARTESiA randomised controlled trial.
In a prespecified ARTESiA subgroup (n=346 with prior stroke/TIA), apixaban reduced annual stroke/systemic embolism to 1.20% vs 3.14% with aspirin (HR 0.40), yielding a 7% absolute risk reduction at 3.5 years but with a 3% absolute increase in major bleeding; benefit in those without prior cerebrovascular events was smaller (1% absolute).
Impact: Provides randomized evidence to guide anticoagulation decisions in high-risk device-detected subclinical AF (prior stroke/TIA), an area of prior uncertainty, and supports apixaban for secondary prevention with explicit risk–benefit numbers.
Clinical Implications: For patients with device-detected subclinical AF and prior stroke/TIA, clinicians should consider apixaban for secondary prevention after individualized bleeding risk assessment and shared decision-making; in patients without such history, net benefit is smaller and warrants caution.
Key Findings
- In SCAF patients with prior stroke/TIA (n=346), apixaban annual stroke/SE 1.20% vs 3.14% with aspirin (HR 0.40).
- Absolute risk reduction at 3.5 years: 7% in those with prior stroke/TIA (vs 1% without).
- Major bleeding annual rate higher with apixaban in prior stroke/TIA subgroup (2.26% vs 1.16%); absolute increase at 3.5 years ~3%.